The pace of progress in hematology has increased enormously in the last few years, making the annual American Society of Hematology (ASH) congress in early December one of the biggest stages for biopharma to unveil its most exciting advances.
Attending this gigantic event and keeping up with the most compelling data presentations is a taxing business; so much so...






